The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
The Binding Specificity and Selective Antagonism of Vedolizumab, an Anti-α4β7 Integrin Therapeutic Antibody in Development for Inflammatory Bowel Diseases
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Unravelling the pathogenesis of inflammatory bowel disease
Xavier, R. J., & Podolsky, D. K. (2007) · Nature · doi:10.1038/nature06005 · Cited by 4,364
A Genome-Wide Association Study Identifies IL23R as an Inflammatory Bowel Disease Gene
Duerr, R. H., Taylor, K. D., Brant, S. R., Rioux, J. D., Silverberg, M. S., Daly, M. J., Steinhart, A. H., Abraham, C., Regueiro, M., Griffiths, A., et al. (2006) · Science · doi:10.1126/science.1135245 · Cited by 3,039
Lymphocyte Homing and Homeostasis
Butcher, E. C., & Picker, L. J. (1996) · Science · doi:10.1126/science.272.5258.60 · Cited by 2,846
Leonardi, C. L., Kimball, A. B., Papp, K. A., Yeilding, N., Guzzo, C., Wang, Y., Li, S., Dooley, L. T., & Gordon, K. B. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60725-4 · Cited by 1,874
Papp, K. A., Langley, R. G., Lebwohl, M., Krueger, G. G., Szapary, P., Yeilding, N., Guzzo, C., Hsu, M.-C., Wang, Y., Li, S., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60726-6 · Cited by 1,361
A Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
Miller, D. H., Khan, O. A., Sheremata, W. A., Blumhardt, L. D., Rice, G. P. A., Libonati, M. A., Willmer-Hulme, A. J., Dalton, C. M., Miszkiel, K. A., & O'Connor, P. W. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020696 · Cited by 1,242
Kleinschmidt-DeMasters, B. K., & Tyler, K. L. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051782 · Cited by 1,072
Progressive Multifocal Leukoencephalopathy after Natalizumab Therapy for Crohn's Disease
Van Assche, G., Van Ranst, M., Sciot, R., Dubois, B., Vermeire, S., Noman, M., Verbeeck, J., Geboes, K., Robberecht, W., & Rutgeerts, P. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051586 · Cited by 1,060
The IL-23/IL-17 axis in inflammation
Iwakura, Y. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28508 · Cited by 1,046
Progressive Multifocal Leukoencephalopathy in a Patient Treated with Natalizumab
Langer-Gould, A., Atlas, S. W., Green, A. J., Bollen, A. W., & Pelletier, D. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051847 · Cited by 1,034
Natalizumab Induction and Maintenance Therapy for Crohn's Disease
Sandborn, W. J., Colombel, J. F., Enns, R., Feagan, B. G., Hanauer, S. B., Lawrance, I. C., Panaccione, R., Sanders, M., Schreiber, S., Targan, S., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043335 · Cited by 927
Natalizumab for Active Crohn's Disease
Ghosh, S., Goldin, E., Gordon, F. H., Malchow, H. A., Rask-Madsen, J., Rutgeerts, P., Vyhnálek, P., Zádorová, Z., Palmer, T., & Donoghue, S. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020732 · Cited by 808
Sandborn, W. J., Feagan, B. G., Fedorak, R. N., Scherl, E., Fleisher, M. R., Katz, S., Johanns, J., Blank, M., & Rutgeerts, P. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.07.014 · Cited by 753
Treatment of Ulcerative Colitis with a Humanized Antibody to the α 4 β 7 Integrin
Feagan, B. G., Greenberg, G. R., Wild, G., Fedorak, R. N., Paré, P., McDonald, J. W. D., Dubé, R., Cohen, A., Steinhart, A. H., Landau, S., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042982 · Cited by 692
Lymphocyte Trafficking and Regional Immunity
(1999) · Advances in Immunology · doi:10.1016/s0065-2776(08)60022-x · Cited by 674
Natalizumab for the Treatment of Active Crohn’s Disease: Results of the ENCORE Trial
Targan, S. R., Feagan, B. G., Fedorak, R. N., Lashner, B. A., Panaccione, R., Present, D. H., Spehlmann, M. E., Rutgeerts, P. J., Tulassay, Z., Volfova, M., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.024 · Cited by 614
Immune surveillance in multiple sclerosis patients treated with natalizumab
Stüve, O., Marra, C. M., Jerome, K. R., Cook, L., Cravens, P. D., Cepok, S., Frohman, E. M., Phillips, J. T., Arendt, G., Hemmer, B., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20858 · Cited by 434
Picarella, D., Hurlbut, P., Rottman, J., Shi, X., Butcher, E., & Ringler, D. J. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.5.2099 · Cited by 362
Expression and function of the MAdCAM-1 receptor, integrin alpha 4 beta 7, on human leukocytes.
Erle, D. J., Briskin, M. J., Butcher, E. C., Garcia-Pardo, A., Lazarovits, A. I., & Tidswell, M. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.153.2.517 · Cited by 355
Regulatory T-cell compartmentalization and trafficking
Wei, S., Kryczek, I., & Zou, W. (2006) · Blood · doi:10.1182/blood-2006-01-0177 · Cited by 346
Hesterberg, P., Winsor-Hines, D., Briskin, M., Soler-Ferran, D., Merrill, C., Mackay, C., Newman, W., & Ringler, D. (1996) · Gastroenterology · doi:10.1053/gast.1996.v111.pm8898653 · Cited by 323
Treatment of Active Crohn's Disease With MLN0002, a Humanized Antibody to the α4β7 Integrin
Feagan, B. G., Greenberg, G. R., Wild, G., Fedorak, R. N., Paré, P., McDonald, J. W. D., Cohen, A., Bitton, A., Baker, J., Dubé, R., et al. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.06.007 · Cited by 285
Progressive Multifocal Leukoencephalopathy and Natalizumab — Unforeseen Consequences
Berger, J. R., & Koralnik, I. J. (2005) · New England Journal of Medicine · doi:10.1056/nejme058122 · Cited by 271
Stüve, O., Marra, C. M., Bar-Or, A., Niino, M., Cravens, P. D., Cepok, S., Frohman, E. M., Phillips, J. T., Arendt, G., Jerome, K. R., et al. (2006) · Archives of Neurology · doi:10.1001/archneur.63.10.1383 · Cited by 271
Schweighoffer, T., Tanaka, Y., Tidswell, M., Erle, D. J., Horgan, K. J., Luce, G. E., Lazarovits, A. I., Buck, D., & Shaw, S. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.151.2.717 · Cited by 253
Progressive multifocal leukoencephalopathy revisited: Has the disease outgrown its name?
Koralnik, I. J. (2006) · Annals of Neurology · doi:10.1002/ana.20933 · Cited by 243
Natalizumab effects on immune cell responses in multiple sclerosis
Niino, M., Bodner, C., Simard, M., Alatab, S., Gano, D., Kim, H. J., Trigueiro, M., Racicot, D., Guérette, C., Antel, J. P., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20859 · Cited by 210
Engelhardt, B., Laschinger, M., Schulz, M., Samulowitz, U., Vestweber, D., & Hoch, G. (1998) · Journal of Clinical Investigation · doi:10.1172/jci4271 · Cited by 203 · cited 2×
“…of IBD, and the molecular mechanisms by which these lymphocytes enter the gut are distinct from those in other peripheral tissues, such as the skin and central nervous system (Butcher and Picker, 1996; Engelhardt et al., 1998; Engelhardt and Briskin, 2005; Salmi and Jalkanen, 2005; Agace, 2006).”
BackgroundZohren, F., Toutzaris, D., Klärner, V., Hartung, H., Kieseier, B. C., & Haas, R. R. (2008) · Blood · doi:10.1182/blood-2007-10-120329 · Cited by 193
Martin, M. D. P. (2008) · Archives of Neurology · doi:10.1001/archneur.65.12.noc80051 · Cited by 181
Tissue-tropic effector T cells: generation and targeting opportunities
Agace, W. W. (2006) · Nature Reviews Immunology · doi:10.1038/nri1869 · Cited by 180
Lazarovits, A. I., Moscicki, R. A., Kurnick, J. T., Camerini, D., Bhan, A. K., Baird, L. G., Erikson, M., & Colvin, R. B. (1984) · The Journal of Immunology · doi:10.4049/jimmunol.133.4.1857 · Cited by 148
Ransohoff, R. M. (2005) · Nature Neuroscience · doi:10.1038/nn1005-1275 · Cited by 141
Lymphocyte homing to the gut: attraction, adhesion, and commitment
Salmi, M., & Jalkanen, S. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00285.x · Cited by 103
Farstad, I. N., Halstensen, T. S., Kvale, D., FAUSA, O., & Brandtzaeg, P. (1997) · PubMed Central · Cited by 97
Integrin α4β7 mediates human eosinophil interaction with MAdCAM‐1, VCAM‐1 and fibronectin
Walsh, G. M., Symon, F. A., LAZAROVITS, A. I., & Wardlaw, A. J. (1996) · Immunology · doi:10.1046/j.1365-2567.1996.d01-713.x · Cited by 86
Tidswell, M., Pachynski, R. K., Wu, S. W., Qiu, S., Dunham, E. K., Cochran, N. A., Briskin, M., Kilshaw, P. J., Lazarovits, A. I., Andrew, D. P., et al. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.159.3.1497 · Cited by 85
Progressive multifocal leukoencephalopathy: lessons from AIDS and natalizumab
Berger, J. R., & Houff, S. A. (2006) · Neurological Research · doi:10.1179/016164106x98198 · Cited by 76
Rott, L. S., BRISKIN, M. J., & Butcher, E. C. (2000) · PubMed · Cited by 69
Kilshaw, P. J. (1999) · Molecular Pathology · doi:10.1136/mp.52.4.203 · Cited by 66
Rott, L. S., BRISKIN, M. J., & Butcher, E. C. (2000) · Journal of Leukocyte Biology · doi:10.1189/jlb.68.6.807 · Cited by 65
CD4+CD25+Foxp3+ regulatory T cells: from basic research to potential therapeutic use
Mottet, C., & Golshayan, D. (2007) · Swiss Medical Weekly · doi:10.4414/smw.2007.11916 · Cited by 62
Natalizumab and progressive multifocal leucoencephalopathy
Berger, J. R. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.058404 · Cited by 57
Therapeutic anti‐integrin (α4 and αL) monoclonal antibodies: two‐edged swords?
González‐Amaro, R., Mittelbrunn, M., & Sánchez‐Madrid, F. (2005) · Immunology · doi:10.1111/j.1365-2567.2005.02225.x · Cited by 51
Engelhardt, B., & Briskin, M. (2005) · European Journal of Immunology · doi:10.1002/eji.200535195 · Cited by 24
Cited by
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
Feagan, B. G., Rutgeerts, P., Sands, B. E., Hanauer, S., Colombel, J.-F., Sandborn, W. J., Van Assche, G., Axler, J., Kim, H.-J., Danese, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215734 · Cited by 2,888
Self-citationVedolizumab as Induction and Maintenance Therapy for Crohn's Disease
Sandborn, W. J., Feagan, B. G., Rutgeerts, P., Hanauer, S., Colombel, J.-F., Sands, B. E., Lukas, M., Fedorak, R. N., Lee, S., Bressler, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215739 · Cited by 2,719
Baumgart, D. C., & Sandborn, W. J. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60026-9 · Cited by 2,154
The safety of vedolizumab for ulcerative colitis and Crohn's disease
Colombel, J.-F., Sands, B. E., Rutgeerts, P., Sandborn, W., Danese, S., D'Haens, G., Panaccione, R., Loftus, E. V., Sankoh, S., Fox, I., et al. (2017) · Gut · doi:10.1136/gutjnl-2015-311079 · Cited by 806
Sands, B. E., Feagan, B. G., Rutgeerts, P., Colombel, J.-F., Sandborn, W. J., Sy, R., D’Haens, G., Ben-Horin, S., Xu, J., Rosario, M., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.05.008 · Cited by 715
Metadata
- Authors
- Soler, D., Chapman, T., Yang, L.-L., Wyant, T., Egan, R., & Fedyk, E. R.
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 2009-09
- Volume
- 330
- Issue
- 3
- Pages
- 864-875
- ISSN
- 0022-3565 (ISSN-L)
- OpenAlex
- W2160619682
- Cited by
- 456
- References
- 45
- FWCI
- 4.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.